Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Gene | KMT2A |
Variant | rearrange |
Impact List | unknown |
Protein Effect | unknown |
Gene Variant Descriptions | KMT2A rearrangement indicates an unspecified rearrangement of the KMT2A gene. |
Associated Drug Resistance | |
Category Variants Paths |
KMT2A mutant KMT2A rearrange |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
KMT2A rearrange FLT3 exon 14 ins | acute myeloid leukemia | sensitive | Revumenib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Revumenib reduced the leukemia burden and improved survival in an acute myeloid leukemia cell line xenograft model harboring a KMT2A rearrangement (MLL-r) and FLT3-ITD compared to vehicle-treated, but only inhibited cell viability after prolonged treatment in culture (PMID: 35017466). | 35017466 |
KMT2A rearrange FLT3 exon 14 ins | acute myeloid leukemia | sensitive | Revumenib + Venetoclax | Preclinical - Cell line xenograft | Actionable | In a preclinical study, the combination of Revumenib and Venclexta (venetoclax) reduced the leukemia burden and improved survival in an acute myeloid leukemia cell line xenograft model harboring a KMT2A rearrangement and FLT3-ITD compared to either treatment alone, and demonstrated synergy in culture, resulting in decreased viability (PMID: 35017466). | 35017466 |